Potentiation by neuropeptide Y of 5HT2A receptor-mediated contraction in porcine coronary artery

European Journal of Pharmacology

Volumn 544, Issue 1-3, 2006, Pages 111-117

  Tsurumaki, Tatsuru ^a   Nagai, Shingo ^a,b   Bo, Xu ^a   Toyosato, Akira ^a   Higuchi, Hiroshi ^a  

^a Course for Molecular and Cellular Medicine ^*  (Japan)

^b Department of Sensory and Integrative Medicine   (Japan)

Author keywords

5 HT; Contraction; Coronary artery; Endothelium; Neuropeptide Y; TXA2

Indexed keywords

15 CYCLOPENTYL 14 OXO 13 AZA 16,17,18,19,20 PENTANORPINANE THROMBOXANE A2; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 2 (BENZO[1,3]DIOXOL 5 YL) N (4 ISOPROPYLPHENYLSULFONYL) 2 (6 METHYL 2 PROPYLPYRIDIN 3 YLOXY)ACETAMIDE; 4 TERT BUTYL N [5 (2 METHOXYPHENOXY) 6 (4 OXOBUTOXY)PYROMIDINE 4 YL]BENZENESULFONAMIDE; 97 618; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; INDOMETACIN; N(G) NITROARGININE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NITRIC OXIDE SYNTHASE INHIBITOR; OZAGREL; PROSTAGLANDIN SYNTHASE INHIBITOR; PROSTANOID RECEPTOR; SERATRODAST; SEROTONIN; SEROTONIN 2A RECEPTOR; THROMBOXANE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY CONSTRICTION; DRUG POTENTIATION; FEMALE; MALE; NONHUMAN; PRIORITY JOURNAL; SWINE; VASOCONSTRICTION;

ANIMALS; CORONARY VESSELS; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; MALE; MYOCARDIAL CONTRACTION; NEUROPEPTIDE Y; NITROARGININE; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ENDOTHELIN; SWINE; THROMBOXANE A2; THROMBOXANE-A SYNTHASE;

EID: 33746633842     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.06.036     Document Type: Article

References (37)

1. Baxter G., Kennett G., Blaney F., and Blackburn T. 5-HT2 receptor subtypes: a family re-united?. Trends Pharmacol. Sci. 16 (1995) 105-110
2. 2-receptor agonist, U-46619. Br. J. Pharmacol. 110 (1993) 360-368
3. Cortés V., Donoso M.V., Brown N., Fanjul R., López C., Fournier A., and Huidobro-Toro J.P. Synergism between neuropeptide Y and norepinephrine highlight sympathetic cotransmission: studies in rat arterial mesenteric bed with neuropeptide Y, analogs, and BIBP3226. J. Pharmacol. Exp. Ther. 289 (1999) 1313-1322
4. Côté F., Fligny C., Fromes Y., Mallet J., and Vodjdani G. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol. Med. 10 (2004) 232-238
5. Edvinsson L., Håkanson R., Wahlestedt C., and Uddman R. Effects of neuropeptide Y on the cardiovascular system. Trends Pharmacol. Sci. 8 (1987) 231-235
6. 2A receptors in 5-HT-induced contraction of endothelium-denuded rabbit epicardial coronary arteries. Br. J. Pharmacol. 122 (1997) 875-884
7. Fabi F., Argiolas L., Ruvolo G., and del Basso P. Neuropeptide Y-induced potentiation of noradrenergic vasoconstriction in the human saphenous vein: involvement of endothelium generated thromboxane. Br. J. Pharmacol. 124 (1998) 101-110
8. 1-selective antagonist, BIBP3226. Br. J. Pharmacol. 119 (1996) 1313-1318
9. 2 antagonist, sarpogrelate hydrochloride, shows inhibitory effects on both contraction and relaxation mediated by 5-HT receptor subtypes in porcine coronary arteries. Pharmacology 61 (2000) 263-268
10. Grundemar L., Jonas S.E., Mörner N., Högestätt E.D., Wahlestedt C., and Håkanson R. Characterization of vascular neuropeptide Y receptors. Br. J. Pharmacol. 105 (1992) 45-50
11. Gu J., Polak J.M., Adrian T.E., Allen J.M., Tatemoto K., and Bloom S.R. Neuropeptide tyrosine (NPY)-a major cardiac neuropeptide. Lancet 7 (1983) 1008-1010
12. Hassall C.J.S., and Burnstock G. Immunocytochemical localization of neuropeptide Y and 5-hydroxytryptamine in a subpopulation of amine-handling intracardiac neurons that do not contain dopamine β-hydroxylase in tissue culture. Brain Res. 422 (1987) 74-82
13. Hieble J.P., Duesler J.G., and Daly R.N. Effects of neuropeptide Y on the response of isolated blood vessels to norepinephrine and sympathetic field stimulation. J. Pharmacol. Exp. Ther. 250 (1989) 523-528
14. Jackerott M., and Larsson L.-I. Immunocytochemical localization of the NPY/PYY Y1 receptor in enteric neurons, endothelial cells, and endocrine-like cells of the rat intestinal tract. J. Histochem. Cytochem. 45 (1997) 1643-1650
15. Macho P., Perez R., Huidobro-Toro J.P., and Domenech R.J. Neuropeptide Y (NPY): a coronary vasoconstrictor and potentiator of catecholamine-induced coronary constriction. Eur. J. Pharmacol. 167 (1989) 67-74
16. Malmström R.E., Hökfelt T., Björkman J.-A., Nihlén C., Byström M., Ekstrand A.J., and Lundberg J.M. Characterization and molecular cloning of vascular neuropeptide Y receptor subtypes in pig and dog. Regul. Pept. 75-76 (1998) 55-70
17. Martin S.E., and Patterson R.E. Coronary constriction due to neuropeptide Y: alleviation with cyclo-oxygenase blockers. Am. J. Physiol. 257 (1989) H927-H934
18. Martin S.E., Kuvin J.T., Offenbacher S., Odle B.M., and Patterson R.E. Neuropeptide Y and coronary vasoconstriction: role of thromboxane A2. Am. J. Physiol. 263 (1992) H1045-H1053
19. Michel M.C., Beck-Sickinger A., Cox H., Doods H.N., Herzog H., Larhammar D., Quirion R., Schwartz T., and Westfall T. International union of pharmacology recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic polypeptide receptors. Pharmacol. Rev. 50 (1998) 143-150
20. Myers A.K., Farhat M.Y., Vaz C.A., Keiser H.R., and Zukowska-Grojec Z. Release of immunoreactive-neuropeptide Y by rat platelets. Biochem. Biophys. Res. Commun. 155 (1988) 118-122
21. Nilsson T., Longmore J., Shaw D., Pantev E., Bard J.A., Branchek T., and Edvinsson L. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur. J. Pharmacol. 372 (1999) 49-56
22. Nilsson T., Lind H., Brunkvall J., and Edvinsson L. Vasodilation in human subcutaneous arteries induced by neuropeptide Y is mediated by neuropeptide Y Y1 receptors and is nitric oxide dependent. Can. J. Physiol. Pharm. 78 (2000) 251-255
23. Nishio H., Inoue A., and Nakata Y. Binding affinity of sarpogrelate, a new antiplatelet agent, and its metabolite for serotonin receptor subtypes. Arch. Int. Pharmacodyn. Ther. 331 (1996) 189-202
24. Ohnuki A., and Ogawa Y. Differential modulation by the endothelium of contractile responses to 5-hydroxytryptamine, noradrenaline, and histamine in the rabbit isolated basilar artery. Gen. Pharmacol. 28 (1997) 681-687
25. Pernow J., and Modin A. Endothelial regulation of coronary vascular tone in vitro: contribution of endothelin receptor subtypes and nitric oxide. Eur. J. Pharmacol. 243 (1993) 281-286
26. 2 receptor of neuropeptide Y. Eur. J. Pharmacol. 327 (1997) 163-167
27. Prieto D., Benedito S., Simonsen U., and Nyborg N.C.B. Regional heterogeneity in the contractile and potentiating effects of neuropeptide Y in rat isolated coronary arteries: modulatory action of the endothelium. Br. J. Pharmacol. 102 (1991) 754-758
28. Prieto D., Simonsen U., and Nyborg N.C.B. Regional involvement of an endothelium-derived contractile factor in the vasoactive actions of neuropeptide Y in bovine isolated retinal arteries. Br. J. Pharmacol. 116 (1995) 2729-2737
29. Prieto D., Garía-Sacristán A., and Simonsen U. Characterization of NPY receptors mediating contraction in rat intramyocardial coronary arteries. Regul. Pept. 75-76 (1998) 155-160
30. 2 antagonists. Jpn. J. Pharmacol. 87 (2001) 189-194
31. 2-adrenoceptor and NPY receptor-mediated contractions of porcine isolated blood vessels: evidence for involvement of the vascular endothelium. Br. J. Pharmacol. 128 (1999) 1705-1712
32. Tatemoto K., Carlquist M., and Mutt V. Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature 296 (1982) 659-660
33. 1-like receptor mediating contraction in the canine coronary artery. Eur. J. Pharmacol. 300 (1996) 109-112
34. Tsurumaki T., Yamaguchi T., and Higuchi H. Marked neuropeptide Y-induced contractions via NPY-Y1 receptor and its desensitization in rat veins. Vascul. Pharmacol. 39 (2003) 325-333
35. Yang Z., Richard V., von Segesser L., Bauer E., Stulz P., Turina M., and Luscher T.F. Threshold concentrations of endothelin-1 potentiate contractions to norepinephrine and serotonin in human arteries. Circulation 82 (1990) 188-195
36. You J., Edvinsson L., and Bryan Jr. R.M. Neuropeptide Y-mediated constriction and dilation in rat middle cerebral arteries. J. Cereb. Blood Flow Metab. 21 (2001) 77-84
37. Zukowska-Grojec Z., Karwatowska-Prokopczuk E., Rose W., Rone J., Movafagh S., Ji H., Yeh Y., Chen W.T., Kleinman H.K., Grouzmann E., and Grant D.S. Neuropeptide Y: a novel angiogenic factor from the sympathetic nerves and endothelium. Circ. Res. 83 (1998) 187-195